Valorie F. Chan

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

E. Donnall Thomas, Henry Gómez, Rubi K. Li et al. · Journal of Clinical Oncology · 2007 · 483 citations · Full text

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

Richard H. De Boer, Óscar Arrieta, James Chih‐Hsin Yang et al. · Journal of Clinical Oncology · 2011 · 289 citations

Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

Sandra M. Swain, Young‐Hyuck Im, Seock‐Ah Im et al. · The Oncologist · 2014 · 67 citations · Full text

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Gabriel N. Hortobágyi, Henry Gómez, Rubi K. Li et al. · Breast Cancer Research and Treatment · 2010 · 66 citations · Full text

Drug Resistance Analysis, Antibiotics, Overall Survival +9